The Fight for Affordable Medicine: Hospitals Take On 340B Program Changes

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

A New Hope for Kidney Disease Patients? FDA Greenlights Voyxact, But Pricing Questions Linger

The Shifting Sands of Pharma and Biotech: Navigating a Dynamic Job Market

The Evolving Pharmaceutical Frontier: Navigating 2025's Landmark Shifts and Enduring Challenges

The Great Pharmaceutical Gridlock: How Patents Keep Prices Sky-High and Biosimilars at Bay

The Weight of Expectation: FDA, Obesity Drugs, and the Uneasy Dance Between Speed and Safety

The Great Weigh-In: Pharma's Fierce Battle for the Future of Obesity, and What Else Keeps Them Up at Night

The Pharmaceutical Whirlwind: From Weight Loss Wonders to Mind-Altering Medicines, A New Era Unfolds

When States Take on Drug Prices: Connecticut's Bold Move and the Unfolding Legal Drama

Gilead Halts HIV Drug Price Hikes Amidst Growing Scrutiny and Public Pressure

The Revolving Door: Ex-FDA Regulators Find New Homes at Pharma Giants Like Eli Lilly

The High-Stakes Battle Over Elevidys: Efficacy, Ethics, and the Future of Rare Disease Drugs

The Pharmaceutical Tsunami: How a Second Trump Term Could Reshape Drug Pricing, Medicare, and Vaccines

STAT+: Sen. Sanders, others lawmakers open probe into asthma inhaler makers over pricing, patent maneuvers

STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers